Clinical Trials
325 trialsTesting What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Johnson & Johnson Enterprise Innovation Inc.
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
OrigAMI-4
Janssen Research & Development, LLC
LUMIRAY
Johnson & Johnson Enterprise Innovation Inc.
OrigAMI-5
Janssen Research & Development, LLC
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Calico Life Sciences LLC
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
PIKALO-1
Eli Lilly and Company
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Case Comprehensive Cancer Center
ERBIOTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment
Memorial Sloan Kettering Cancer Center
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Merus B.V.
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
FORTIFI-HN01
Bicara Therapeutics
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
University of Miami
DUAL-HN
Beijing Biotech
A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
STELLAR-002
Exelixis
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
AFAN
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
JADE
GlaxoSmithKline
eVOLVE-02
AstraZeneca
AHEAD-MERIT
BioNTech SE
NEXUS-01
Eli Lilly and Company
INVOKE
Epkin
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
ILLUMINE
Groupe Oncologie Radiotherapie Tete et Cou
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
Medical University of South Carolina
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
AbbVie
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono
REDUCE-30
University of Cincinnati
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Eastern Cooperative Oncology Group
PRORADNOR-RCT
Oslo University Hospital
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
OP-NEU-101
Onchilles Pharma Inc
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
EPSACO
Centre Hospitalier Universitaire, Amiens
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca